Figure 3

miR-3151 and BAALC expression and outcome in younger IR-AML patients. (a) The optimal cut-off level for BAALC expression as identified by the MaxStat package. (b) Overall survival according to BAALC expression levels. (c) Overall survival according to the combination of miR-3151 and BAALC expression levels. (d) leukemia-free survival according to the combination of miR-3151 and BAALC expression levels. (e) Cumulative incidence of relapse according to the combination of miR-3151 and BAALC expression levels.